Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase II trial PNET HR+5.

Christelle DufourStephanie FoulonAnne GeoffrayJulien Masliah-PlanchonDominique Figarella-BrangerValerie Bernier-ChastagnerLaetitia PadovaniLéa Guerrini-RousseauCecile Faure-ConterCeline IcherAnne-Isabelle BertozziPierre LeblondTasnime AkbaralyFranck BourdeautNicolas AndréCeline ChappéPascale SchneiderEmilie De CarliPascal ChastagnerClaire BergerJulien LejeuneChristine SolerNatacha Entz-WerléMarie-Bernadette Delisle

Published in: Neuro-oncology (2021)

This treatment based on high-dose chemotherapy and conventional radiotherapy resulted in a high survival rate in children with newly diagnosed high-risk medulloblastoma.

Keyphrases

newly diagnosed
high dose
risk factors
young adults
locally advanced
early stage
low dose
randomized controlled trial
stem cell transplantation
squamous cell carcinoma
radiation induced
combination therapy